Results 221 to 230 of about 232,884 (341)
Cardio‐microcurrent device treatment for heart failure with reduced ejection fraction: Results from the C‐MIC II open‐label randomized controlled trial
European Journal of Heart Failure, EarlyView.Efficacy and Safety of C‐MIC Device in Patients with Heart Failure with Reduced Ejection Fraction. 6MWD, 6‐min walk distance; CI, confidence interval; KCCQ‐OSS, Kansas City Cardiomyopathy Questionnaire overall summary score; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.Jesus E. Rame, Jan D. Schmitto, Dragana N. Kosevic, Tamara Kovacevic‐Preradovic, Sasko Jovev, Marija Zdravkovic, Nermir Granov, Tanja Popov, Igor Rudez, Petar Vukovic, Velibor Ristic, Petr Neuzil, Annette Holtdirk, Arjang Ruhparwar, Muhammad Shahzeb Khan, Hans‐Dirk Düngen, Kersten Brandes, Peter Goettel, Johannes Mueller, Faouzi Kallel, Tim Friede, Miodrag Peric, Marat Fudim, Stefan D. Anker, for the C‐MIC II Trial Investigators +24 morewiley +1 more sourceSomatic Mutations in <i>MCOLN3</i> Are Associated With Aldosterone-Producing Adenomas. [PDF]
Hypertensionvan Rooyen D, Bandulik S, Coon GA, Laukemper M, Kumar-Sinha C, Udager AM, Lerario AM, Lee C, Wachtel H, Cohen DL, Luther JM, Giordano TJ, Scholl UI, Butz F, Popp B, Turcu AF, Warth R, Rainey WE, Rege J. +18 moreeuropepmc +1 more sourcePrognostic significance of somatic mutations in myeloid cells of men with chronic heart failure – interaction between loss of Y chromosome and clonal haematopoiesis
European Journal of Heart Failure, EarlyView.Abstract Aims
Age‐associated clonal haematopoiesis of indeterminate potential (CHIP) has been linked to increased incidence and worse prognosis of chronic heart failure (CHF). CHIP arises from somatic mutations in haematopoietic stem and progenitor cells. Mosaic loss of Y chromosome (LOY), the most common somatic mutation in male blood cells, increases Sebastian Cremer, Moritz von Scheidt, Klara Kirschbaum, Lukas Tombor, Silvia Mas‐Peiro, Wesley Abplanalp, Tina Rasper, Akshay Ware, Andrin Schuff, Alexander Berkowitsch, Johannes Krefting, David Leistner, Heribert Schunkert, Thimoteus Speer, Stefanie Dimmeler, Andreas Michael Zeiher +15 morewiley +1 more sourceEfficacy and Safety of Aldosterone Synthase Inhibitors in Hypertension: A Systematic Review and Meta-Analysis. [PDF]
Endocrinol Diabetes MetabGoh JS, Sohail S, Ayub H, Cheema ZZ, Paray NB, Adikari S, Mesmar A, Atout M, Qazi AR, Aldalqamouni A, Younas B, Rauf MA, Khan MAW, Abouayana A, Abouayana AEA, Hasan A, Shahzad M, Ahmed M, Ahmed R, Ahmed S. +19 moreeuropepmc +1 more sourceRandomized investigation of heart failure therapy in patients with advanced cancer at risk of cardiac wasting: Rationale and design of the EMPATICC trial
European Journal of Heart Failure, EarlyView.EMPower the heArt of patients with TermInal Cancer using Cardiac medicines (EMPATICC). eGFR, estomated glomerular filtration rate; EP, endpoint; FCM, ferric carboxymaltose; LVEF, left ventricular ejection fraction; N‐terminal pro‐B‐type natriuretic peptide; PGA, patient global assessment; PoC, proof of concept; QoL, quality of life; UICC, Union for ...Markus S. Anker, Amir A. Mahabadi, Matthias Totzeck, Mitra Tewes, Raluca Mincu, Muhammad Shahzeb Khan, Javed Butler, Ulrich Keller, Johann Ahn, Lars Bullinger, Dominik P. Modest, Ulf Landmesser, Lorenz H. Lehmann, Sven Bercker, Ulrich Laufs, Michael Böhm, Bela Merkely, Monika Diek, Tim Heise, Martin Hellmich, Marius Placzek, Tim Friede, Stefan D. Anker, Tienush Rassaf +23 morewiley +1 more source